CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 206 enrolled
Drug / intervention
Fiberoptic bronchoscopy and bronchoalveolar lavageprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00248443
NCT00248443Phase 3Completed
CompareCT.gov

Severe Acute Respiratory Failure in Hematology and Cancer Patients Without Bronchoalveolar Lavage. A Multicentric Randomized Controlled Trial

Assistance Publique - Hôpitaux de Paris·interventional·Posted Nov 4, 2005·Updated Feb 18, 2011

In Brief

A Phase 3 clinical trial evaluating Fiberoptic bronchoscopy and bronchoalveolar lavage for Lymphoma and 3 related conditions. Completed, enrolled 206 participants across 1 site.

Detailed Summary

The MiniMax® study is a multicenter randomized controlled study aimed at demonstrating that a combination of non-invasive diagnostic tools are as effective as fiberoptic bronchoscopy and bronchoalveolar lavage (FO-BAL) in performing the etiological diagnosis of acute respiratory failure in cancer patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Cancer, Acute Respiratory Failure, Leukemia
CountriesFrance
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 4, 2005
Enrollment StartAug 1, 2005
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 20.7 years ago

Interventions

Fiberoptic bronchoscopy and bronchoalveolar lavageprocedure